-

OM1’s PhenOM® Foundation AI Surpasses One Billion Years of Health History in Model Training

BOSTON--(BUSINESS WIRE)--OM1, a leading provider of AI-driven insights for life sciences and healthcare organizations, today announced a major milestone in the development of its groundbreaking PhenOM® Foundation Model. The model has now been trained on more than one billion years of patient health histories, representing the largest model of its kind to date.

PhenOM is a next-generation AI platform that identifies patient phenotypes and accurately predicts diagnoses, outcomes, and treatment effects at scale. By analyzing structured and unstructured data from diverse healthcare sources, the PhenOM API delivers real-time predictions on thousands of outcomes from hospitalizations to heart attacks and strokes across a wide range of diseases and populations.

“Training AI models on real-world health data at this scale opens up unprecedented opportunities to improve how we predict, diagnose, and treat disease,” said Dr. Richard Gliklich, CEO of OM1. “PhenOM is not just a model, it’s an adaptive foundation layer built on billions of clinical events, enabling intelligent healthcare applications and research across the entire ecosystem.”

In addition to predicting outcomes, the PhenOM model evaluates the safety and benefits of treatments in specific patients and subpopulations. This enables healthcare stakeholders to identify underdiagnosed or undertreated patients, improve clinical trial efficiency, and support precision health initiatives.

OM1’s innovation in AI-driven real-world evidence is underpinned by a strong and expanding intellectual property portfolio. Eight U.S. patents have been issued to date for OM1’s technologies, with a ninth patent scheduled to issue on May 20, 2025, further strengthening the company’s position as a leader in applied clinical AI. OM1 is currently working with a range of partners, including leading healthcare systems, health plans, life sciences organizations, and software companies, to integrate PhenOM into programs that target population health, value-based care, and drug development.

Meet our PhenOM experts and learn more at ISPOR 2025, booth #1500.

About OM1:

OM1 is pioneering cutting-edge healthcare innovation through its insights-driven technology and data. It specializes in personalized medicine, evidence generation, and real-world evidence (RWE) research powered by next-generation AI platforms, deep longitudinal data, and globally recognized thought leadership. OM1 is led by a diverse group of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWE.

Contacts

Media:
Kristine Christie
Vice President Marketing
kchristie@om1.com
Om1.com

OM1


Release Versions

Contacts

Media:
Kristine Christie
Vice President Marketing
kchristie@om1.com
Om1.com

More News From OM1

OM1 to Present Groundbreaking Research on GLP-1 Agonists and Suicidal Ideation at ISPOR 2025

BOSTON--(BUSINESS WIRE)--OM1: What: OM1, the leader in real-world data and AI-driven insights in mental health for life sciences, announced an upcoming poster presentation hosted by Jessica Probst, OM1’s Principal, Real World Evidence. The poster focuses on the linkage between Glucagon-like Peptide 1 Receptor Agonists (GLP-1s) and Suicidal Ideation (SI). Consistent with other findings and despite warnings on the label, there was no significant increase in SI prevalence after GLP-1 initiation. W...

OM1 Adds 1 Million Patients to Its Mental Health Network, Significantly Expanding Specialty Coverage and Driving New Possibilities for Real-World Research and Personalized Care

BOSTON--(BUSINESS WIRE)--OM1, the leader in real-world data and AI-driven insights for mental health, today announced a significant expansion of its specialty mental health network, adding over one million patients, making it the largest, most clinically rich network of its kind. This milestone deepens OM1’s ability to power high-quality, representative, and timely real-world evidence (RWE) to support better decision-making in life sciences and healthcare. “Access to large, longitudinal, and re...

OM1 Expands into Europe to Strengthen Support for Life Sciences with AI-Driven Real-World Evidence Solutions

BOSTON--(BUSINESS WIRE)--OM1, a leading provider of real-world data (RWD) and AI-driven insights for life sciences, today announced its expansion into Europe to better support pharmaceutical and healthcare organizations with high-quality, AI-enhanced real-world evidence (RWE) solutions. This step marks a significant milestone in OM1’s mission to improve healthcare decision-making by providing more actionable, data-driven insights across a wider geographic area. OM1’s expansion into Europe respo...
Back to Newsroom